Reddit Posts
$GANX Gain Therapeutics, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Mentions
is $GANX rippin' today?
Great info. We should get the data we expected in Q4 and then extended data at AD/PD. Gain Therapeutics(GANX): Final countdown to Phase 1b data at January 6th KOL Event https://gaintherapeutics.wordpress.com/2025/12/20/gain-therapeuticsganx-final-countdown-to-phase-1b-data-at-january-6th-kol-event/
Crazy man. I got stopped out last week with a very small loss on RVPH but MIST and GANX really fucked me up. I didn't lose a lot of money, but I lost my profits. Should have set a tighter stop loss which sucks too. Biotech can be a slippery slope for sure.
I’ve seen a fair amount of DD on GANX but the fact that the company is literally called Gain is the most convincing.
GANX is the only good one i have seen here
Came here to say GANX and FEMY are the two I am most strongly behind.
$GANX so much potencial. DYOR
See also PTRN, NAVN MIAX was one of the most successful IPOs this year, don't see that going away anytime soon I'm going to bet with money that ANET and SKYT do well. Haven't done it yet. GANX is my only bag on this list, asymmetric risk bet, especially with the crazy sell off last week. They'll get bought out this year, calling it now
Depends on the circumstances. Impossible to time perfectly, but momentum trading allows you to snipe on the upside. I watch a few tickers that are volatile TGB & GANX have made money for me lately. Others I keep long term and just buy on a regular schedule GLD has done well for me. I do own VOO & SCHD as stalwarts.
Depends on what you consider going to the moon. For me that probably means a triple in a year. Not bags, as I am tripled already, but GANX could triple or lose 2/3 soon. As in next 3 months. Debating whether to sell part of my position and freeroll. I also like HROW to double, and CRDOF could easily double. If you asked me which of my holdings would be most likely to double this year I would say CRDOF. I already got a triple off it this year.
Now that we now know how impressive the biomarker improvement was we can look forward to seeing more data at upcoming KOL event. Gain Therapeutics(GANX): ROTH MKM Thought on Phase 1b data: Raising price target to $10 https://gaintherapeutics.wordpress.com/2025/12/19/gain-therapeuticsganx-roth-mkm-thought-on-phase-1b-data-raising-price-target-to-10/ joeiniowa@gmail.com
GANX has insane short squeeze potential, 50% of shares traded yesterday were shorts. Already 6M over daily volume average and stock just took a 14% dip from daily high. Needs buying pressure. Could very well see $3.25 by EOD
GANX short squeeze
Insane short squeeze opportunity for $GANX
Yeah me too. I made a little off BYND but not that much. Live and learn. Yeah I felt like MIST and GANX had good news and still tanked. That's frustrating as hell. Definitely high risk high reward plays.
Thoughts on FGI, GANX, SLS today?
RIP to all you GANX holders
Extension doesn't mean they can't start PII before september, it means that patients wanted to continue the drug (80% of those enrolled in the trial - 15 out of 19). That's pretty positive, means most patients didn't have bad enough negative side effects to make them want to stop. I believe this means they're eschewing other treatment options while the trial continues (but correct me if I'm wrong) which would indicate they feel the drug is having a net positive effect. Clinical team will monitor ths group on the 1B rubric - which is primarily focused on "is this pill safe to take regularly" but may also track symptomatic data. However, even improvements are not worth much without a true double blind placebo trial. For investors, the stock is still as risky as any 1B / PII drug company would be. Lots of them fail in this process. Not a sure bet. For GANX today, I think people were expecting to see anecdotes of widespread symptomatic improvement in this trial report. Frankly, unrealistic. What we got instead was the encouraging data that the drug \*may be\* on the right track with reducing GluSph. I remain cautiously optimistic and still invested.
Gain (GANX) therapeutics already jumping back up! Probably just panic sell in combination with already high valuation of stock, make sure to buy some before it gets acquired by a large partner for the process of stage 2 trials.
Al those positive news stock drops GANX, FEMY,...
SLS and GANX both primed to rip 10-20x
Curious how you’re thinking about dilution risk here as GANX reported only about $8.8M in cash as of Sept 30 with ongoing net losses and stated they’ll need additional financing to operate beyond Q1 2026. They also have an active ATM/equity program up to $35.5M authorized, and have already raised capital under it this year. Your thoughts?
I’ve waited just under a couple of years for this data, since I bought my first $GANX share…so a couple of days, or weeks…yes I can definitely do that. All signs point to a positive read out. How positive? We’ll find out soon. I really hope for those suffering with Parkinson’s, that this will really be the first chink in its armour!
Yes, and GANX RSI was in overbought territory for 6 days in a row. It’s cooled off now (see bottom of screenshot). I think there's a good chance it dips again tomorrow, maybe down to $3.65, before it begins heading back upwards and finishes solid green. \~$3.65 is the bottom support of the trading channel it's been in been in since early November. Of course, this goes out the window if data is released in the morning. But I think the set-up is good for a Thursday release, possibly Friday. The winds will be at their backs again from a technical perspective. https://preview.redd.it/zyq3pgkzum7g1.jpeg?width=1277&format=pjpg&auto=webp&s=e8e50a613860713f55d9ae77875de56a8e2a5d3c
GANX and DRTS is my portfolio til 2026
BNAI, GANX, OTLK about to tank because I bought in
You're welcome. Also, check out TE. I just lost a bunch on short dated calls so I'm a bit salty about the company, but it was up 60% in one week before they did a share offering at the current price. This is very likely to go back up a lot, basically they are at the same price from a week ago but with a lot more cash on hand. My mistake was getting out at the top, then going right back in when it dipped a little without checking the news. This is a good entry point though, and it will pump as soon as the NASDAQ recovers. One other stock with potential catalysts this week is GANX, there's some good dd on reddit
I bought 500 shares of GANX when I first heard it at a conference sponsored by the Michael J Fox Foundation in October 2024. It was at around $2.10 and I promised myself (my mother died of Parkinsons) that I would donate my profits to the MJFF. after it became a long term gain. I think it will go up a bit more but I'm going to sell in January.
I see this market sell off as a buying opportunity for stocks you have conviction in. I have conviction in GANX.
I love that I’ve been seeing more posts about GANX recently because what they’re doing is awesome. Jumped in late November and pick up more on every dip
Always good to get another perspective from someone who analyzes biotechs professionally. One unique thing about GANX that makes it stand out form other biotechs, is there is virtually no bear case. Usually there are bears that come out to argue why such and such a drug is unlikely to work. There is none of that here. Too much pre-clinical and clinical data, plus new studies, that make this a hard drug to bet against.
SLS $2.5 Jan 16 call and GANX $5 Jan 16 call. SLS more likely to be a higher % return. NFA and there's no reason to listen to me but hey, yolo
GANX developing a drug for parkinsons disease Currently 4$ , the CEO says that even if the share is at 20$ its a buy
Gotta throw it out there- the last yolo for 2025 is GANX. Their insane results are going to get them bought out.
My top right now are VKTX SYRE for mid caps GANX is a good small cap also
Thanks for the DD as always. I can’t see a better risk/reward in the market. Really looking forward to seeing the biomarker data. It’s about time that I’m seeing more $GANX on Reddit…some stocks just don’t get picked up as much as others. For me, this is still a hidden gem, and even if it’s up 130% in the last few months, anyone buying today, its still relatively early in game. Phase 1 biotech, so yes there’s risk, but it would be a major curveball for the phase 1b data to not be a net positive for the stock.
Load up on GANX before the boom. Steady and constant price improvement in anticipation of further results. Buyout imminent
I know what you mean, and I've been burned before. But I've also never done as much DD and have never been more confident in a stock as I am with $GANX. See my explanation on why I think this is de-risked. But, of course, do your own DD. I think this easily doubles from here on data readout, and then gets bought at $20 or higher. But I'm much less certain about the exact future prices than I am about... higher.
Dude, you're the only actual person out of all the comments here. I checked. Years of gaps for the older accounts, until a month ago Spam posting GANX for 2 accounts. This sub is so Fucked.
Here is some recent info. Gain Therapeutics(GANX): Updated Analyst Reports with All Eyes on Biomarker readout in Q4 https://gaintherapeutics.wordpress.com/2025/11/16/gain-therapeuticsganx-updated-analyst-reports-with-all-eyes-on-biomarker-readout-in-q4/
Im in GANX at 2.90 ill look into DRTS
Im in GANX and DRTS and locked in profits, now just waiting to see what the future holds
GANX: the 5 day looks so clean
GANX. Phase 1b for Parkinson’s medicine great results so far
If you like mist check out GANX.
If there's a slight dip, big GANX buy.
Perfect timing for $GANX. I've made a bunch of posts on this and why this is a great asymmetric risk/reward opportunity over the next two weeks (data release), and then beyond that for likely buyout or partnership.
I only have three stocks that I'm investing in with the way the market reacted to Burry/NVDA situation (not saying he's wrong, everything is overpriced), and my time horizon is similar since I think we will start seeing some of the cracks in the system in the short term. One of them will probably get me banned for mentioning, but GOOGL, ASTS, and GANX. ASTS has already shot back from the dip, so remain skeptical. Google is a safety net. The other is speculative buyout based on the results of their most recent study, and they're announcing more very soon. High risk high reward.
GANX has a phase 1 study that is giving Parkinson’s patients their sense of smell back. 100m market cap t the moment.
This comment by the analyst on the three unique models that all show Gains GT-02287 works in Parkinson's is worth reading. Very important. Gain Therapeutics(GANX): H.C. Wainwright $8 PT 12/1/25 Three Month Data Imminent https://gaintherapeutics.wordpress.com/2025/12/01/gain-therapeuticsganx-h-c-wainwright-8-pt-12-1-25-three-month-data-imminent/
Honestly, the “placebo = dopamine surge” explanation sounds scientific on the surface, but it doesn’t really line up with what we’re seeing in this trial. Placebo dopamine effects in Parkinson’s are real, but they’re short-lived, like usually hours to a few days, and they tend to fade, not strengthen, over time. They also don’t restore smell, don’t improve multiple functions months after dosing, and definitely don’t line up with changes in lysosomal or mitochondrial biomarkers. What people are reporting with GANX showed up after 60–90 days, not right away, which is the opposite of a typical placebo timeline. The improvements clinicians mentioned such as better balance, tremors quieting down, and even smell returning, aren’t things dopamine placebo spikes can sustain. Smell loss in PD has nothing to do with dopamine; it’s tied to lysosomal dysfunction and misfolded proteins. That’s exactly the pathway GANX is targeting by restoring GCase activity and mitochondrial function. So when patients start improving months into treatment, that fits the biology of a drug that repairs cellular machinery, not a short-term psychological response. If all we had were a couple of hopeful anecdotes, I’d get the placebo caution. But when you combine the timing, the type of improvements, the consistency across multiple patients, and the fact that GANX already showed GCase and mitochondrial restoration in human volunteers and patient-derived cells, the placebo theory just stops making sense. A dopamine placebo can’t fix lysosomes, mitochondria, or long-term motor function, it fades too fast and doesn’t touch those systems at all. We still need the biomarker readout, and that’s exactly what will separate hype from reality. But based on what we know so far, the “it’s all dopamine placebo” explanation doesn’t really hold up. This pattern looks a lot more like a real biological effect than a fleeting psychological one.
I am saying Gene is the CEO of a microcap company repeating what hopeful patients and enthusiastic clinicians told him in an unblinded setting. That is not science; that is Investor Relations. Of course he is going to highlight the positive stories. You said: "It's not just smell... it's balance, tremors and motor functions." Exactly. That reinforces the placebo theory; it doesn't disprove it. Parkinson's is a dopamine-deficiency disease. The placebo effect in PD works by triggering the brain's reward system to release endogenous dopamine. What does dopamine fix? Tremors, balance, rigidity, and gait. If a patient has a strong placebo response, all of those things improve simultaneously. It is not magic, and it is not unique to this drug. It is biology I am not saying the drug definitely doesn't work. I am saying that every single thing you listed—tremor reduction, better balance, subjective smell return—can be fully explained by the dopamine-loop of an open-label trial. That is why the FDA requires Phase 2. If you want to bet that these anecdotes are unique to GANX, that is your call, but history suggests caution.
You asked for a reference study on neuron recovery? There isn’t one because no drug has ever reversed Parkinson’s in humans. That’s exactly the point. But we know basic neurobiology, for example from trauma patients after bad car accidents and others: structural repair (neuroplasticity/axonal regrowth) is a slow, biological process. If you take Levodopa, you improve in 30 minutes. That’s symptomatic. If you claim to repair mitochondrial function and clear aggregates (disease modification), that should take months or years to translate into motor benefits. Seeing a rapid jump in function at 90 days screams "symptomatic effect" (or placebo), not "neuron recovery." Regarding the extension and patient expectations: You are ignoring the most famous case in PD history—the **Bristol GDNF trial**. In that trial, patients felt so much better they swore they were cured. They moved better. They had their lives back. When the trial ended, they and their families protested and petitioned to keep the infusion ports in their heads because they didn't want to lose the benefit. Result? It turned out the most vocal improvements were often in the placebo group or statistically insignificant compared to placebo. Patients stay in extensions because they feel better. I am not denying the GANX patients feel better. I am questioning WHY. Is it the molecule? Or is it the potent cocktail of hope, better medical care, and the dopamine reward system? Until you run a blinded control arm, you cannot answer that. History says betting against the placebo effect in PD is a losing trade.
Need to get more action on GANX
The comments from Gianrico Farrugia on the new pharmacological science behind GANX made several weeks ago were very encouraging - it looks like they are reorganizing the entire scientific research on the Mayo Clinic website - I will post when they repost it all
I’ll admit I hold a very small postion in this stock, so it’s not like I would go all in. But your bearish case for GANX is based on: 1) wrong number of patients 2) the behavior of my other bio stocks in the past Yeah no thanks
Yeah, I saw your other post and this comment and it reads like someone that’s trying to save their book, most likely because you have a short position and are getting wrecked. Some of the info is flat-out wrong and misleading. 1. Claim: “N=1 PRKN, 1–3 point UPDRS = noise” We’re not dealing with just one PRKN patient anymore. Gain’s December corporate deck shows 21 patients enrolled and 9 patients with 90-day MDS-UPDRS data, with a mean improvement of about –4.6 points on Part II+III at Day 90, and no acute dopaminergic bump at Day 30. Multiple PD studies treat roughly a 3–5 point improvement on MDS-UPDRS Part III as clinically meaningful. So saying “1–3 points is indistinguishable from noise” doesn’t align with actual PD clinical standards. 2. Claim: “Placebo effect makes this meaningless” True, PD has a strong placebo effect, but the numbers are being exaggerated. Yes, some trials have seen up to 20–30 percent placebo improvement, but that is the extreme end. A meta-analysis of blinded PD trials shows the average placebo improvement is closer to around 4 UPDRS motor points. Also, the GANX Phase 1b pattern is the opposite of a classic placebo spike. There was no benefit at Day 30 but a growing improvement by Day 90 in patients already on stable PD meds. Placebo responses are usually front-loaded, not delayed. And Gain is not presenting Phase 1b as proof of efficacy; it’s safety plus biomarker plus functional signal to justify a randomized Phase 2. 3. Claim: “Venglustat failed, so this will too” Comparing venglustat to GT-02287 is scientifically inaccurate. They are entirely different mechanisms: Venglustat is a GCS inhibitor. It lowers substrate synthesis upstream. It reached target engagement but failed in the MOVES-PD trial, showing no benefit and possibly worsening progression. [Sources: MOVES-PD trial results] GT-02287 is an allosteric modulator of GCase itself. It stabilizes the misfolded enzyme, restores lysosomal function, and importantly, repairs mitochondrial pathways. The 2025 Neuroscience poster on Gain Therapeutics website shows GT-02287 increases mitochondrial GCase, restores complex I activity in severe L444P patient-derived cells, improves mitochondrial membrane potential, reduces ROS and cytochrome-c release, and protects dopaminergic neurons in MPP+ models. Independent research in Nature Communications also confirms that GCase is imported into mitochondria and is essential for complex I stability, reinforcing the mitochondrial mechanism that Gain is targeting. 4. Claim: “Other PD drugs like alpha-syn antibodies failed, so this will too” This comparison also doesn’t hold. Prasinezumab and cinpanemab were extracellular alpha-syn antibodies given to patients already far into disease progression. Targeting downstream aggregates didn’t slow disease enough in those studies. GT-02287 is targeting an upstream, genetically validated mechanism (GBA1) that affects lysosomal and mitochondrial failure. It has shown: • Target engagement in humans (53 percent increase in GCase in healthy volunteers by Day 14). • Preclinical rescue in both GBA1-mutant and idiopathic PD models. People should always be cautious with early-phase biotech, but framing GANX as if it’s nothing more than a placebo blip or “another venglustat” isn’t supported by the actual biology or the updated clinical data. If you want to argue valuation or risk profile, that’s fair but the scientific claims you made don’t match the real sources.
If your interested in doing any DD and read the facts start here. All of the above are based on a Reddit comment that is trying to be used to form a short thesis. Gain Therapeutics(GANX): Updated Analyst Reports with All Eyes on Biomarker readout in Q4 https://gaintherapeutics.wordpress.com/2025/11/16/gain-therapeuticsganx-updated-analyst-reports-with-all-eyes-on-biomarker-readout-in-q4/
N=1? Source? Absolutely not true. You think a company would conduct a study with one patient? https://gaintherapeutics.com/wp-content/uploads/2025/12/Corporate-Deck-GANX-December.pdf Slide 16
GANX touching $3.999 now, slow and steady and great support/resistance testing. Still a speculative play but think this goes large as more data comes out
Wow, Praxis was trading around $50 in mid-October and was over a billion dollar market cap at the time. Now at $248. Yes, the rotation is definitely happening. Perfect storm set-up is right. Good timing for GANX. Will add Praxis to my watch list.
Yo dude just saw your comment, quick question: I know GANX Q3 was trash but I’m still with you on the thesis. Is right now still a solid entry or am I late to the party?
That makes two of us. $GANX 💪🏼
GANX has potential to go large in the next year
Every poster in here comment history is talking nothing but GANX.
Careful about this one. Always check post history of commenters for GANX and you will find tons of bot accounts posting nothing about this stock.
Have a look at GANX. Not saying buy for the sake of buying, but look it up
Here is latest info including H.C. Wainwright update. Very interesting comments by him. Gain Therapeutics(GANX): Updated Analyst Reports with All Eyes on Biomarker readout in Q4 https://gaintherapeutics.wordpress.com/2025/11/16/gain-therapeuticsganx-updated-analyst-reports-with-all-eyes-on-biomarker-readout-in-q4/
Just opened a position on GANX.
Novel mechanism may also give us clues for other neurological diseases. Alzheimer’s has been a tough nut to crack, Crutzfeldt-Jakob, ALS are still enigmatic. GANX compounds could provide insights.
Don't miss out on GANX. Im in at 2.85
GANX gonna graduate from Pennyland soon
Janx went down over 50% yesterday on news of some delays. Analysts say it was an overreaction, stock is barely outside of penny territory. Also GANX might pop, there s serious dd on it if you guys want to look
I told myself the same thing, yet I got back in with GANX. The weird thing is— and I certainly could be wrong— I think this is one of my lower risk stocks in the near term, and the one with the biggest imminent upside.
GANX break-out attempt
GANX only not breaking due to ATM-offering; that stock is coiling
GANX boarding for take-off to the moon